Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer-Reference-Cited by-同舟云学术

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer

Published:2015-01 Issue:2 Volume:51 Page:218-224
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vassal Gilles,Rousseau Raphaël,Blanc Patricia^ORCID,Moreno Lucas^ORCID,Bode Gerlind,Schwoch Stefan,Schrappe Martin,Skolnik Jeffrey^ORCID,Bergman Lothar,Bradley-Garelik Mary Brigid,Saha Vaskar,Pearson Andy,Zwierzina Heinz

Funder

Cancer Research UK Life Chair and Programme Grant

NIHR RM/ICR Biomedical Research Centre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda;Vassal;Pediatr Blood Cancer,2014

2. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries;Pritchard-Jones;Lancet Oncol,2013

3. Children with cancer: driving the global agenda;Pritchard-Jones;Lancet Oncol,2013

4. Childhood cancer survival in Europe: action is needed;Gatta;Epidemiol Prev,2013

5. Long-term cause-specific mortality among survivors of childhood cancer;Reulen;JAMA,2010

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Crucial Role of Patient Advocates in Pediatric Oncology Research—Insights From ACCELERATE;JAMA Pediatrics;2024-09-01

2. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

3. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer;Journal of Clinical Oncology;2024-07-20

4. Refractory/Relapsed AML in Children and Evolution of Novel Therapies;Pediatric Oncology;2024

5. Policy of pediatric oncology drug development;Essentials of Translational Pediatric Drug Development;2024